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Abstract
Background: Small heat shock proteins are molecular chaperones that protect proteins against
stress-induced aggregation. They have also been found to have anti-apoptotic activity and to play a
part in the development of tumors. Recently, we identified a new small heat shock protein, Hsp16.2
which displayed increased expression in neuroectodermal tumors. Our aim was to investigate the
expression of Hsp16.2 in different types of brain tumors and to correlate its expression with the
histological grade of the tumor.
Methods: Immunohistochemistry with a polyclonal antibody to Hsp16.2 was carried out on
formalin-fixed, paraffin-wax-embedded sections using the streptavidin-biotin method. 91 samples
were examined and their histological grade was defined. According to the intensity of Hsp16.2
immunoreactivity, low (+), moderate (++), high (+++) or none (-) scores were given.
Immunoblotting was carried out on 30 samples of brain tumors using SDS-polyacrylamide gel
electrophoresis and Western-blotting.
Results:  Low grade (grades 1–2) brain tumors displayed low cytoplasmic Hsp16.2
immunoreactivity, grade 3 tumors showed moderate cytoplasmic staining, while high grade (grade
4) tumors exhibited intensive cytoplasmic Hsp16.2 staining. Immunoblotting supported the above
mentioned results. Normal brain tissue acted as a negative control for the experiment, since the
cytoplasm did not stain for Hsp16.2. There was a positive correlation between the level of Hsp16.2
expression and the level of anaplasia in different malignant tissue samples.
Conclusion: Hsp16.2 expression was directly correlated with the histological grade of brain
tumors, therefore Hsp16.2 may have relevance as becoming a possible tumor marker.
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Background
Most malignant neoplasms in the brain already carry a
dismal prognosis when they are diagnosed. Therefore, the
treatment of human brain tumors possesses a continuous
challenge for oncological research. Although several brain
tumor markers have been studied as possible prognostic
factors, further study is needed to reveal the complex
mechanism of tumor genesis, thus helping to discover the
most appropriate tumor markers for prognosticating the
neoplasm.
Small heat shock proteins have been noted for their pos-
sible role in the development of tumors [1,2]. Function-
ally these proteins are molecular chaperones that prevent
the stress induced aggregation of denatured proteins, thus
protecting protein function and activity[3,4]. Further-
more, sHSPs have anti-apoptotic activity, which -if overex-
pressed in tumor cells – could lead to increased tumor
growth, a resistance to chemo- or radiotherapy and to the
unfortunate outcome of the disease [5-8].
Previously we identified and characterized a novel small
heat shock protein (Hsp16.2) [9]. Overexpression of
Hsp16.2 protected cells against various stress stimuli (e.g.
hydrogen peroxide, taxol) by the stabilization of the mito-
chondrial membrane system and the inhibition of caspase
3 activation. It was also demonstrated that the anti-apop-
totic effect of Hsp16.2 is mediated by the activation of
Hsp90, with which Hsp16.2 binds, and by the activation
of the PI-3 kinase-Akt pathway. Furthermore, overexpres-
sion of Hsp16.2 increased lipid rafts formation, thus help-
ing to stabilize the plasma membrane [9,10].
Preliminary studies indicated that Hsp16.2 is expressed in
neuroectodermal tumors [9]. In the present paper we
study the different types of brain tumors including benign
and malignant meningeoma, oligodendroglioma, gliob-
lastoma multiforme, ependymoma and medulloblast-
oma. Using immunohistochemistry method and Western
blot analysis we determined the expression of Hsp16.2
and its intracellular localization in the tumor cells. Our
aim was to examine whether the level of Hsp16.2 expres-
sion correlates with the malignancy of the brain tumor.
This study provides evidence for the role of Hsp16.2 as a
possible marker for brain tumors.
Methods
Tumor materials
Brain tumor samples from ninety-one patients were avail-
able for examination. All tumor tissue specimens were
provided by the Medical University of Pécs, Department
of Neurosurgery and Pathology. Full ethical approval was
given by the Regional Research Ethics Committee of the
Medical Center of Pécs (Approval Number: 030630). for
the use of these samples. Each type of tumor was identi-
fied according to the revised WHO classification of Histo-
logical Typing of the Tumors of the Central Nervous
System (2007) [11].
Preparation of polyclonal antibodies against Hsp16.2
Rabbits were immunized subcutaneously at multiple sites
with 100 pg of recombinant Hsp16.2/GST fusion protein
which was expressed as it was described before [9,10] in
Freund's complete adjuvant. Four subsequent booster
injections at 4-week intervals were given with 50 pg of
protein in Freund's incomplete adjuvant. Blood was col-
lected 10 days after boosting, and the antiserums were
stored at -20 C. IgGs were affinity purified from sera by
protein G-Sepharose chromatography according to the
manufacturer's protocol.
Immunohistochemistry
Sections from the tumor tissue samples were formalin-
fixed and paraffin-embedded. Subsequently, they were
incubated with polyclonal anti-Hsp16.2 polyclonal anti-
body. Immunohistochemical staining was carried out
according to the streptavidin-biotin-peroxidase method
with hydrogen peroxide/3-amino-9-ethylcarbazole devel-
opment using the Universal kit. Only secondary IgG was
incubated with the control sections. The evaluation of the
slides was done with the help of an Olympus BX50 light
microscope with incorporated photography system
(Olympus Optical Co., Hamburg, Germany). Both the
presence and localization of positive staining for Hsp16.2
was examined. Staining intensity was recorded semiquan-
titatively as mild (+), moderate (++) or strong (+++), fol-
lowing as it was described before [12]. For internal
positive control, the normal cerebral and vascular struc-
tures of the samples were used. Positive areas around
necrotic fields were excluded due to their probable stress
related up-regulation.
Immunoblot analysis
Tumor tissue specimens were homogenized in chilled
lysis buffer of 0,5 mM sodium metavanadate, 1 mM
EDTA, and protease inhibitor mixture in phosphate-buff-
ered saline in a Teflon/glass homogenizer, and centri-
fuged. Isolation of cytosol and nuclear fractions were
carried out by standard lab protocols exactly as previously
[13]. The samples were equalized to 1 mg/ml total protein
concentration using Biuret's method and subjected to
SDS-PAGE. Proteins (20 μg/lane) were separated on 15%
gels and then transferred to nitrocellulose membranes.
The membranes were blocked in 5% low fat milk for 1 h
at room temperature, then exposed to the primary anti-
Hsp16,2 antibodies at 4°C overnight at a dilution of
1:2,000 in blocking solution. Appropriate horseradish
peroxidase-conjugated secondary antibodies were used
for 2 h at room temperature and at 1:5,000 dilution. Per-
oxidase labeling was visualized with enhanced chemilu-BMC Cancer 2007, 7:233 http://www.biomedcentral.com/1471-2407/7/233
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minescence (ECL) using an ECL Western blotting
detection system (Amersham Biosciences). The developed
films were scanned, and the pixel volumes of the bands
were determined using NIH Image J software. All experi-
ments were repeated four times.
Statistical analysis
Difference in distribution of variables between groups was
tested using χ2 test. Values of p < 0.01 were considered to
be significant.
Results
Expression and intracellular localization of Hsp16.2 in 
different brain tumors by immunohistochemistry
Ninety-one samples of different brain tumors were evalu-
ated in the present study (Table 1): 5 schwannomas
(grade 1), 6 pilocytic astrocytomas (grade 1), 6 menin-
gothelial meningeomas (grade 1), 5 fibrous meningeo-
mas (grade 1), 8 diffuse astrocytomas (grade 2), 5
oligodendrogliomas (grade 2), 6 ependymomas (grade
2), 5 atypical meningeomas (grade 2), 6 malignant
meningeomas (grade 3), 5 anaplastic astrocytomas (grade
3), 5 anaplastic oligodendrogliomas (grade 3), 9 glioblas-
tomas (grade 4), 5 giant cell glioblastomas (grade 4), 8
medulloblastomas (grade 4) and 7 PNETs (primitive neu-
roectodermal tumor) (grade 4).
Hsp16.2 immunoreactivity was found both in the nucleus
and in some cases in the cytoplasm in tumor tissues (Fig.
1). Since intranuclear labeling was present in all tumor
samples in large quantities, cytoplasmic Hsp16.2 immu-
noreactivity could be used for differential diagnostic pur-
poses. Cytoplasmic labeling varied considerably among
the different histological types and grades of tumors. Low
grade tumors (grades 1–2) showed weak or no staining
(+/-) in the cytoplasm (Fig. 1.A,B). There was no detecta-
ble Hsp16.2 in the cytoplasm of the benign schwannoma
(Fig. 1.A) and one pilocytic- (Fig 1.B) and two diffuse
astrocytomas. The remaining low grade tumors stained
weakly (Fig. 1.C,E), excepting ependymomas (Fig. 1.G)
and atypical meningeomas, which stained moderately
(++).
Grade 3 tumors, including malignant meningeomas (Fig.
1.F), anaplastic astrocytomas (Fig 1.D) and oligodendro-
gliomas (Fig. 1.H), displayed moderate cytoplasmic
immunoreactivity for Hsp16.2. (++). High grade tumors
(grade 4) such as glioblastomas (Fig. 1.I), medulloblasto-
mas and PNETs (Fig. 1.J) exhibited strong Hsp16.2 posi-
tivity in the cytoplasm. (+++)
Table 2 shows the correlation between the cytoplasmic
staining and the histological grades of different brain
tumors.
There was no cytoplasmic expression in 63.6% and mild
expression in 36.4% of Grade 1 cancers. 16.6 % showed
no, 45.8% exhibited mild and 37.6% of the samples dis-
played moderate staining in Grade 2 cancers. All (100%)
Grade 3 cancers demonstrated moderate staining. Only
6.9% of Grade 4 tumor samples revealed moderate immu-
noreactivity, while 93.1% proved to be intensively
stained. These results clearly demonstrate that the
Hsp16.2 staining of the cytoplasm is directly correlated
with the histological grade of the brain tumors.
Table 1: Immunohistochemical analysis of Hsp16.2 in 51 human brain tumors.
Histological diagnosis No. of cases Tumor grade Intracytoplasmic labeling Intranuclear labeling
- + ++ +++ - + ++ +++
Schwannoma 5 1 5 5
Pilocytic astrocytoma 6 1 3 3 6
Meningothelial meningioma 6 1 4 2 6
Fibrous meningeoma 5 1 2 3 5
Diffuse astrocytoma 8 2 3 5 8
Oligodendroglioma 5 2 1 4 5
Ependymoma 6 2 1 5 1 5
Atypical meningeoma 5 2 1 4 5
Malignant meningeoma 6 3 6 6
Anaplastic astrocytoma 5 3 5 5
Anaplastic oligodendroglioma 5 3 5 5
Glioblastoma 9 4 2 7 9
Giant cell glioblastoma 5 4 5 5
Medulloblastoma 8 4 8 8
PNET 7 4 7 7
Staining intensity: (+) mild, (++) moderate, (+++) strongBMC Cancer 2007, 7:233 http://www.biomedcentral.com/1471-2407/7/233
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Expression and intracellular distribution of Hsp16.2 in different human tumors of the nervous system Figure 1
Expression and intracellular distribution of Hsp16.2 in different human tumors of the nervous system. Immunohistochemistry utilizing anti-
Hsp16.2 primary antibody was performed on 91 brain tumor samples. A. Schwannoma. Intensive intranuclear Hsp16.2 immunoreactivity, whereas no 
immunoreactivity in the cytoplasm. B. Pilocytic astrocytoma. Strong intranuclear immunopositivity but no intracytoplasmic staining was detected. C. Grade 
2 astrocytoma shows intensive intranuclear labeling as well as mild cytoplasmic staining. D. Grade 3 astrocytoma exhibits strong Hsp 16.2 positivity intra-
nuclearly and moderate Hsp16.2 positivity in the cytoplasm. E. Grade 1 meningeoma showing high expression of Hsp16.2 intranuclearly and mild expres-
sion in the cytoplasm. F. Grade 3 meningeoma displayed strong intranuclear and moderate cytoplasmic staining for Hsp16.2. G. Grade 2 ependymoma 
with strong intranuclear and moderate cytoplasmic immunopositivity. H. Grade 3 oligodendroglioma exhibiting intensive intranuclear and moderate cyto-
plasmic immunoreactivity. I. Grade 4 glioblastoma showing strong Hsp16.2 positivity intranuclearly and intracytoplasmically alike. J. Grade 4 PNET with 
intensive staining in the nucleus as well as in the cytoplasm.BMC Cancer 2007, 7:233 http://www.biomedcentral.com/1471-2407/7/233
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Detection of Hsp16.2 expression by Western-blot
After subcellular fractionation, the expression of Hsp16.2
was determined from both the cytosolic (Fig. 2) and the
nuclear fraction by immunoblotting. Thirty samples were
studied including three from normal brain tissue, and
three samples from nine different types of brain tumors.
The intranuclear expression of Hsp16.2 was approxi-
mately the same level in the different samples (data not
shown). Three samples from different parts of the brain
were tumor-free, serving as a negative control for the
experiment, which contained a minimal amount of
nuclear and cytoplasmic Hsp16.2 (lane 1). Low cytoplas-
mic expressions of the protein were visible in grade 1
meningeomas, pilocytic astrocytomas (lane 2, 3). The
expression was stronger in the Grade 2 diffuse astrocyto-
mas and ependymomas (lane 4, 5). Higher cytoplasmic
expressions of Hsp16.2 were observed in grade 3 tumors
such as anaplastic astrocytomas and malignant meninge-
omas (6, 7). The strongest bands appeared in the cytoplas-
mic samples of medulloblastomas, PNETs and
glioblastomas (8–10). In conclusion, the observed
Hsp16.2 labeling correlated with the results gained by the
immunohistochemistry method.
Discussion
Small stress proteins are a group of heat shock proteins
that share an evolutionary conserved C-terminal region,
called the alpha-crystallin domain, and whose molecular
weight ranges between 15 and 43 kDas [1,7,14-16]. They
are known to play a part in cell differentiation and in
counteracting apoptosis [7]. Due to the anti-apoptotic
activity of sHsps, tumor cells expressing the protein highly
may become increasingly resistant to chemo- or radiother-
apy[1,17-19].
A number of recent studies have been concerned with the
possible role of small heat shock proteins in the progres-
sion of brain tumors. Aoyama et al. reported increased
expression of alphaB-crystallin in human glial tumors
such as astrocytomas and glioblastoma multiforme[20].
Astrocytic neoplasms were examined for Hsp27 immuno-
reactivity also. While normal astrocytes showed no Hsp27
immunoreactivity, low Hsp27 expression was found in
benign astrocytomas and elevated levels of Hsp27 found
in poorly differentiated tumors. There are data indicating
the direct correlation between Hsp27 expression and the
histologic grade of astrocytic tumors [17,21-23]. The prog-
nostic significance of Hsp27, Hsp 70, and Hsp90 in
medulloblastomas was examined with equivocally posi-
tive results [24].
Previously, we reported the existence of a novel small
stress protein, sHsp16.2 and its high levels of expression
in neuroectodermal cancers [9]. This finding turned our
Cytoplasmic expression of Hsp16.2 in different human brain tumors Figure 2
Cytoplasmic expression of Hsp16.2 in different human brain tumors. Endogenous cytoplasmic expression levels of Hsp16.2 were assessed by 
Western blotting utilizing a custom made polyclonal anti-Hsp16.2 primary antibody. 30 samples were used including three from normal brain tissue and 18 
samples from nine different types of brain cancer, two samples from each type. The subcellulare fractionation was confirmed by probing with antibodies 
recognizing nuclear H3 histone, cytoplasmic actin and equal loading was confirmed by a second incubation with anti-GAPDH antibody (data not shown). 1: 
normal brain, 2: Pilocytic astrocytoma (Grade 1), 3: Meningothelial meningioma (Grade1) 4: Diffuse astrocytoma (Grade 2), 5: Ependymoma (Grade 2), 6: 
Malignant meningioma (Grade 3), 7: Anaplastic astrocytoma (Grade 3), 8: Medulloblastoma (Grade 4), 9: Giant cell glioblastoma (Grade 4), 10: PNET 
(Grade 4).
Table 2: Correlation of Hsp16.2 cytoplasmic expression and histological grade of brain cancer.
Hsp16.2 
expression
Grade 1
n (%)
Grade 2
n (%)
Grade 3
n (%)
Grade 4
n (%)
Total
n (%)
P Value
- 14 (63.6) 4 (16.6) 18 (19.8) <0.01
+ 8 (36.4) 11(45.8) 19 (20.8)
++ 9 (37.6) 16 (100) 2 (6.9) 27 (29.7)
+++ 27 (93.1) 27 (29.7)
Total 22 (100) 24 (100) 16 (100) 29 (100) 91 (100)
Staining intensity: (+) mild, (++) moderate, (+++) strongBMC Cancer 2007, 7:233 http://www.biomedcentral.com/1471-2407/7/233
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attention to examining sHsp16.2 expression in brain
tumors differing in their grade and type. Since all fifty-one
tumors were labeled equally intra-nuclearly, and they var-
ied in their cytoplasmic labeling, it became apparent that
the various tumors differed in the distribution and density
of sHsp16.2 in the cell cytoplasm. In accordance with ear-
lier studies, astrocytomas (grade 1–2) as well as other
benign brain tumors, such as meningothelial meninge-
oma, and oligodendroglioma (grade 1–2) exhibited low
expression (+) of Hsp16.2. In fact, certain benign brain
tumors, like schwannoma and fibrous meningeoma
showed no immunoreactivity at all. However, the increase
of anaplasia in the tumor cells resulted in moderate (++)
expression (atypical meningeoma, malignant meninge-
oma, anaplastic astrocytoma, anaplastic oligodendrogli-
oma) and high (+++) expression (glioblastoma,
medulloblastoma, PNET) of the protein. Thus, it became
evident that there is a direct correlation between the inten-
sity of the staining and the histological grade of the brain
tumor. Western blot analysis of thirty tumor samples gave
similar results. It was observed, that no Hsp16.2 was
found in normal brain tissue, while high Hsp16.2 labe-
ling was observed in samples from medulloblastoma and
glioblastoma. The observation that low levels were seen in
Grade 1 meningeomas, pilocytic astrocytomas, moderate
levels in grade 2 diffuse astrocytomas and ependynoma,
stronger in grade 3 anaplastic astrocytomas and malignant
melanoma, and elevated levels of Hsp16.2 in grade 4 neo-
plasms indicate that Hsp16.2 protein levels increase with
the grade of the tumor.
According to our findings, Hsp16.2 could be a marker
whose cytoplasmic expression increases as the tumor
progresses. The cytoplasmic expression of the protein cor-
relates directly with the grade of the tumors, it is only
present in tumor cells in significant quantity and its level
increases with the increase of cell anaplasia.
Conclusion
We have found that the Hsp16.2 could become a valuable
marker for primary brain tumor diagnosis and the anti-
apoptotic activity of sHsp16.2 could become the target of
drug therapy. Still, further efforts need to be made to
reveal the exact role and function of sHsp16.2 in tumor
cells. However, the significance of this novel small stress
protein in anti-cancer research seems certain.
List of abbreviations
sHsp, small heat shock protein; PNET, primitive neuroec-
todermal tumor
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